Amgen (AMGN) reported Q4 non-GAAP earnings late Wednesday of $5.31 per diluted share, up from $4.71 a year ago.
Analysts polled by FactSet expected $5.08.
Revenue for the quarter that ended Dec. 31 was $9.09 billion compared with $8.20 billion a year ago.
Analysts expected $8.88 billion.
For 2025, the biotech company is projecting non-GAAP EPS of $20.00 to $21.20 on revenue of $34.3 billion to $35.7 billion.
Analysts are looking for $20.92 and $34.62 billion, respectively.
Amgen shares were declining 2% in after-market activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。